全球白喉-破傷風-百日咳 (DTaP) 疫苗市場規模（按產品類型、年齡層、最終用戶、區域範圍）預測（至 2025 年）

白喉、破傷風和百日咳 (DTaP) 疫苗市場規模和預測

2024 年白喉-破傷風-百日咳 (DTaP) 疫苗市場規模價值 71.8 億美元，預計到 2032 年將達到 67.5 億美元，2026 年至 2032 年的複合年成長率為 7.3%。

• 白喉-破傷風-百日咳 (DTaP) 疫苗是一種聯合疫苗，可預防三種感染疾病：白喉、破傷風和百日咳。建議所有人終生接種這些疫苗。這些疫苗通常作為兒童常規免疫計劃的一部分進行接種。
• 為了保護您的孩子免受破傷風、百日咳和白喉的侵害，您應該接種DTaP疫苗。許多此類疾病可能非常嚴重，尤其是在幼兒中。接種疫苗是預防這些疾病的最佳方法。
• 政府疫苗接種計劃、不斷增強的疫苗接種意識以及疫苗技術的進步是推動 DTaP 疫苗市場發展的一些原因。
• 根據美國國家醫學圖書館介紹，DTaP 疫苗是為 6 週至 6 歲之間的兒童注射的，旨在使他們獲得對 DTaP 的免疫力，如果他們感染某些疫苗可預防的疾病，可能會出現致命或危及生命的併發症。

白喉-破傷風-百日咳（DTaP）疫苗的全球市場動態

影響白喉、破傷風和百日咳 (DTaP) 疫苗市場的關鍵市場動態是：

關鍵市場促進因素

• 增加兒童疫苗接種：由於全球出生率上升以及開發中國家對兒童疫苗接種計劃的興趣增加，接種 DTaP 疫苗的兒童數量大幅增加。
• DTaP 疫苗研發活動：製藥公司不斷研發新的 DTaP 疫苗，包括副作用較少的疫苗和預防百日咳、破傷風、白喉和許多其他疾病的聯合疫苗。
• 提高疫苗接種意識：公共衛生計畫和教育宣傳活動大大提高了人們對疫苗接種價值的認知，尤其是在開發中國家。越來越多的家長選擇按照建議的接種時間表為孩子接種疫苗。
• 政府承諾和資源：為了使疫苗接種更加普及，一些政府已經實施並資助了強力的免疫計劃，特別是在中低收入國家。

主要挑戰

• 疫苗開發成本高：開發、生產和銷售一種新的 DTaP 疫苗成本高昂，這可能會阻礙公司在該領域的投資並阻礙創新。
• 錯誤訊息和疫苗猶豫：網路上的錯誤訊息和疫苗猶豫可能會導致父母推遲或拒絕為孩子接種疫苗，這可能導致避免疾病爆發並降低整體疫苗接種率。
• 供應鏈問題：如果製造商停止生產某些 DTaP 疫苗或遇到某些 DTaP 疫苗的生產問題，複雜的製造流程、難以獲得的原料以及複雜的分銷計劃可能會導致短期供不應求，從而擾亂疫苗接種計劃並可能延遲兒童的保護。
• 新發病株：DTaP百日咳疫苗成分持續演化，新株的出現可能會克服疫苗的保護作用。持續研發和監測以追蹤疾病流行病學的變化並適當調整疫苗配方，對於維持疫苗對新株的有效性至關重要。

主要趨勢：

• 全球疫情防治：COVID-19 疫情凸顯了疫情防治和疫苗接種的重要性。為了改善全球疫苗分配，提高疫苗產量，並強化疫苗供應鏈，各國政府、醫療體系和疫苗製造商正在加大研發和基礎建設的投入。透過加強整體疫苗接種基礎設施建設，並為未來可能出現的疫情做好準備，這些努力有望推動 DTaP 疫苗市場的發展。
• 人工智慧和其他先進技術：DTaP 疫苗開發越來越依賴人工智慧和其他先進技術的使用，這些技術有可能加快研究速度並增強疫苗設計和製造程序。
• 新興市場需求不斷成長：人們對一劑即可預防多種疾病的疫苗越來越感興趣。因此，青少年整體疫苗接種需求將減少，疫苗接種完成率也會提高。五聯疫苗可在DTaP的基礎上增加對B肝和乙型流感的保護。
• 重視新疫苗開發：新型 DTaP 疫苗的研究和開發仍在繼續，包括可能提高療效、免疫持續時間或減少副作用的疫苗。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 白喉-破傷風-百日咳 (DTaP) 疫苗市場（依產品類型）

• DTaP-IPV疫苗
• TD
• Tdap-hEPb-IPV 疫苗

5. 白喉-破傷風-百日咳 (DTaP) 疫苗市場（按年齡層）

• 成人
• 孩子們

6. 白喉-破傷風-百日咳 (DTaP) 疫苗市場（依最終用戶）

• 醫院
• 診所
• 疫苗接種中心

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• GLAXOSMITHKLINE PLC（GSK）
• Sanofi Pasteur
• GlaxoSmithKline
• SERUM INSTITUTE OF INDIA PVT. LTD
• Protein Sciences Corporation
• Novartis AG
• Seqirus（formerly CSL Behring）
• Merck Sharp & Dohme Corp（MSD）
• Astellas Pharma Inc
• Pfizer Inc
• Johnson & Johnson.

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market Size And Forecast

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market size was valued at USD 7.18 Billion in 2024 and is projected to reach USD 6.75 Billion by 2032, growing at a CAGR of 7.3% from 2026 to 2032.

• The Diphtheria, Tetanus, and Pertussis (DTaP) vaccine is a combination vaccine that provides protection against three infectious diseases: diphtheria, tetanus, and pertussis (whooping cough). Even the booster shots are advised throughout life. These vaccinations are normally given to children as part of regular immunization programs.
• To protect kids from tetanus, pertussis, and diphtheria, they must receive the DTaP vaccinations. Particularly in young children, many illnesses have the potential to be serious. The best protection against these illnesses is vaccination.
• Government immunization programs, rising vaccination awareness, and developments in vaccine technology are some of the reasons driving the market for DTaP vaccines.
• According, to National Library of Medicine DTaP vaccine is injected to the 6 weeks to 6 years of age of children's it gives immunity against DTaP. People who are dependent to certain vaccine-preventable illnesses may experience fatal consequences or even life-threatening complications.

Global Diphtheria, Tetanus, and Pertussis Vaccine Market Dynamics

The key market dynamics that are shaping the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market include:

Key Market Drivers:

• Rise in Children Vaccination: The number of children receiving DTaP vaccinations is significantly rising due to rising global birth rates and increased attention on childhood immunization programs in developing nations.
• Research and Development Activities in DTaP Vaccines: Pharmaceutical companies are continually investigating and creating new and enhanced DTaP vaccines. These developments can include vaccines with fewer side effects or combination of doses that offer protection against many diseases in addition to pertussis, tetanus, and diphtheria.
• Growing Awareness Regarding Vaccinations: Public health programs and educational campaigns, especially in developing nations, are greatly raising knowledge of the value of vaccinations. More parents are choosing to vaccinate their children in accordance with suggested timelines.
• Government Initiatives and Resources: To make these vaccinations more widely available, several governments are putting in place robust immunization programs and providing financial assistance. Particularly in low- and middle-income nations is this true.

Key Challenges:

• High Cost of Vaccine Development: The process of investigating, creating, and releasing new DTaP vaccinations is costly. This may reduce the number of businesses making investments in this area could hinder innovation.
• Misinformation and Vaccine hesitation: Parents may decide to postpone or refuse to vaccinate their children as a result of misinformation spreading online and vaccine hesitation. This may lead to avoid disease outbreaks and lower immunization rates overall.
• Supply Chain Issues: Manufacturers discontinuance of some DTaP vaccinations or production problems because of things like complicated manufacturing processes, difficult to find raw materials, and complicated distribution plans might occasionally result in brief shortages of supplies. This may interfere with immunization schedules and postpone kid protection.
• Emerging Disease Strains: As pertussis, a vaccine component in the DTaP, continues to change, new strains of the disease that might overcome vaccination-induced protection are appearing. In order to maintain vaccine efficacy against developing strains, it is essential to conduct ongoing research and monitoring to track changes in disease epidemiology and modify vaccine formulations appropriately.

Key Trends:

• Worldwide Pandemic Preparedness: The COVID-19 outbreak has highlighted the significance of being ready for pandemics and having vaccinations in place. To improve global vaccine distribution networks, boost vaccine manufacturing, and strengthen vaccine supply chains, governments, healthcare systems, and vaccine manufacturers are investing in R&D and infrastructure. By strengthening the entire vaccination infrastructure and preparing for potential future epidemics, these initiatives should help the DTaP vaccine market.
• AI and Other Advanced Technologies: The development of the DTaP vaccine is increasingly reliant on the use of artificial intelligence and other advanced technologies. AI has the potential to expedite research, enhance vaccine design, and vaccine production procedures.
• Growing Demand in Emerging Markets: People are becoming more and more interested in emerging of vaccinations, which offer multi-disease protection in a single dose. As a result, a youngster requires fewer vaccinations overall, and vaccine completion rates rise. Pentavalent vaccinations, which combine DTaP with protection against Hepatitis B and Haemophilus influenza type B.
• Emphasis on Developing New Vaccines: Research and development are continuing to produce new DTaP vaccines with enhanced qualities. This covers vaccinations with increased potency, immunity that lasts longer, or reduced adverse effects.

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Diphtheria, Tetanus, and Pertussis (DTaP) vaccine market:

North America:

• The duration of the forecast period, North America is anticipated to lead the market. This is explained by the fact that North America has a 34.8% market share and is home to many important industry players. Prominent industry participants, including Sanofi, AJ Vaccines A/S, GSK plc, Merck & Co., Inc., and others, are well-represented in this area.
• Due to their extensive public health awareness and well-established pediatric immunization programs, North American countries often have high vaccination rates.
• Patients in North America have greater access to DTaP vaccines because to the generally favorable reimbursement policies of both government and insurance provider providers.

Europe:

• The duration of the projection period, the Europe area is anticipated to rank second in size. Because skin conditions are becoming more common in Europe. For example, a National Library of Medicine report from March 2022 states that 185,103,774 people in Europe had a dermatological ailment or disease in 2021.
• Due to prevalence of dermatological diseases Europe contain DTaP vaccine which offers protection against bacterial illnesses such as pertussis, tetanus, and diphtheria. On the other hand, a variety of skin disorders known as dermatological illnesses are not brought on by these microorganisms.
• Numbers of European nations have firmly developed healthcare systems with strong immunization program infrastructure. European governments have implemented robust immunization policies and provided financial support, thereby facilitating the accessibility of DTaP vaccinations. These reasons contribute to the high immunization rates for DTaP vaccinations in many European nations.

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Segmentation Analysis

The Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market is segmented on the basis of Product Type, Age Group, End User, And Geography.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Product Type

• DTaP-IPV
• TD
• Tdap-hEPb-IPV

Based on the Product Type, the market is distributed into DTaP-IPV, TD and Tdap-hEPb-IPV and Others. Due to increased DTaP vaccine usage and new product launches, the DTaP vaccine segment is anticipated to lead the diphtheria vaccine market throughout the forecast period.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Age Group

• Adult
• Pediatrics

Based on Age Group, the market is segmented into Adult and Pediatrics. During the projection period, the pediatrics category is anticipated to dominate the market, primarily because major players in the industry have increased their research and development expenditure.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By End-User

• Hospitals
• Clinics
• Vaccination Centers

Based on End-User, the market is fragmented into Hospitals, Clinics and Vaccination Centers. The course of the projection period, hospitals are anticipated to dominate the market. This is due to an increase in government measures to open hospital novel wards for the prevention of diphtheria.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is likely to remain a major player in the DTaP vaccine market in the foreseeable future, but the competitive landscape may evolve as other regions develop their markets.

Key Players

• The "Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GLAXOSMITHKLINE PLC (GSK), Sanofi Pasteur, GlaxoSmithKline, SERUM INSTITUTE OF INDIA PVT. LTD, Protein Sciences Corporation, Novartis AG, Seqirus (formerly CSL Behring), Merck Sharp & Dohme Corp (MSD), Astellas Pharma Inc, Pfizer Inc, Johnson & Johnson. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Recent Developments
• In December 2022, the 6-in-1 Hexavalent Vaccine development partnership between BIONET-ASIA, a vaccine manufacturing business, and Pharmaniaga Berhad, a pharmaceutical company based in Malaysia, was announced, with the help of the vaccine. Malaysian healthcare professionals would have the choice to vaccinate children against six common childhood illnesses, including hepatitis B (Hep-B), poliomyelitis (IPV), pertussis (aP), tetanus (TT), and diphtheria (DT).
• In June 2022 , Global pharmaceutical company GSK plc revealed that it has invested over US$ 1.2 billion to speed up research and development (R&D) aimed at creating vaccines and medications to treat and prevent HIV (through ViiV Healthcare), malaria, tuberculosis, neglected tropical diseases (NTDs), and diphtheria.
• In October 2020, a vaccine manufacturer named BIONET-ASIA declared that the Phase-II clinical trials for Tetanus, Diphtheria, and Pertussis (In Children, Prevention) were concluded in Thailand.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By Product Type

• DTaP-IPV
• TD
• Tdap-hEPb-IPV

5. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By Age Group

• Adult
• Pediatrics

6. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By End-User

• Hospitals
• Clinics
• Vaccination Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• GLAXOSMITHKLINE PLC (GSK)
• Sanofi Pasteur
• GlaxoSmithKline
• SERUM INSTITUTE OF INDIA PVT. LTD
• Protein Sciences Corporation
• Novartis AG
• Seqirus (formerly CSL Behring)
• Merck Sharp & Dohme Corp (MSD)
• Astellas Pharma Inc
• Pfizer Inc
• Johnson & Johnson.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References